| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Isopsoralenoside targets multiple pathways. It shows estrogen-like activity, suggesting interaction with estrogen receptors. The compound promotes osteoblastic proliferation, indicating effects on bone metabolism. Its antitumor effects suggest involvement in cancer-related pathways. The antibacterial activity indicates antimicrobial targets. Its rapid metabolism to psoralen suggests that some of its activities may be mediated by its metabolite. Anti-inflammatory and antioxidant activities have also been reported.
|
|---|---|
| ln Vitro |
In vitro, Isopsoralenoside shows estrogen-like activity, promoting osteoblastic proliferation. It demonstrates antitumor effects and antibacterial activity. The compound exhibits anti-inflammatory and antioxidant effects. Its rapid metabolism to psoralen in digestive tract contents is an important characteristic for understanding its bioactivity. Specific IC50 values are not detailed in the available literature.
|
| ln Vivo |
Specific in vivo data for Isopsoralenoside are limited. Given its estrogen-like activity and osteoblastic proliferation-promoting effects, the compound has potential for in vivo studies in models of osteoporosis and bone health. Its antitumor effects suggest potential for cancer research. Its ability to manage skin disorders and support liver health indicates potential for in vivo studies in these areas. However, specific published protocols are not available.
|
| Enzyme Assay |
The estrogen-like activity is assessed using cell-based reporter assays. Cells transfected with estrogen response element (ERE)-driven luciferase reporters are treated with Isopsoralenoside at various concentrations, and luciferase activity is measured. Osteoblastic proliferation is assessed using osteoblast cell lines (e.g., MC3T3-E1) treated with the compound, with cell proliferation measured by MTT or BrdU incorporation assays. Antibacterial activity is assessed using broth microdilution assays.
|
| Cell Assay |
For cellular studies, osteoblast cell lines, cancer cell lines, and bacterial cultures are used. Cells are cultured in appropriate media and treated with Isopsoralenoside at various concentrations (e.g., 0.1-100 μM) for 24-72 hours. Cell viability and proliferation are assessed using MTT or similar assays. For estrogen receptor activity, luciferase reporter assays are performed. For antibacterial testing, bacterial growth is monitored by optical density. The compound is typically dissolved in DMSO and diluted in culture media.
|
| Animal Protocol |
In vivo studies for Isopsoralenoside would be conducted in appropriate animal models. For bone health studies, ovariectomized mouse models of osteoporosis would be used. For antitumor studies, xenograft models would be employed. For skin disorder studies, appropriate dermatological models would be used. The compound would be administered via oral gavage or intraperitoneal injection. However, specific published protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Isopsoralenoside are limited but notable. The compound is rapidly metabolized to psoralen in the digestive tract contents. This suggests that the orally administered compound may act as a prodrug, with psoralen being the active metabolite responsible for at least some of its effects. Pharmacokinetic studies would be required to determine the absorption and metabolism profile.
|
| Toxicity/Toxicokinetics |
As a natural product from Psoralea corylifolia, which has traditional medicinal uses, Isopsoralenoside is generally considered to have a moderate safety profile. However, psoralen, its metabolite, is known to be phototoxic and can cause skin photosensitivity. Comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound should be handled with appropriate safety precautions, particularly protection from UV light.
|
| References | |
| Additional Infomation |
Reports indicate that Isopsoralenoside has been found in Cullen corylifolium, and relevant data is available for reference.
Isopsoralenoside is a benzofuran glycoside from Psoralea corylifolia that is rapidly metabolized to psoralen. It shows estrogen-like activity, promotes osteoblastic proliferation, and demonstrates antitumor and antibacterial effects. No clinical trials exist. For research use only. |
| Molecular Formula |
C17H18O9
|
|---|---|
| Molecular Weight |
366.319426059723
|
| Exact Mass |
366.095
|
| CAS # |
905954-18-9
|
| PubChem CID |
11574162
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
662.4±55.0 °C at 760 mmHg
|
| Flash Point |
354.4±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.711
|
| LogP |
-0.02
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
524
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC2=C(C=CO2)C(=C1/C=C\C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
CAMYXILYLXYDFE-MIVOEOINSA-N
|
| InChi Code |
InChI=1S/C17H18O9/c18-7-11-13(21)14(22)15(23)17(25-11)26-16-8(2-4-12(19)20)1-3-10-9(16)5-6-24-10/h1-6,11,13-15,17-18,21-23H,7H2,(H,19,20)/b4-2-/t11-,13-,14+,15-,17+/m1/s1
|
| Chemical Name |
(Z)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1-benzofuran-5-yl]prop-2-enoic acid
|
| Synonyms |
Isopsoralenoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~272.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7299 mL | 13.6493 mL | 27.2985 mL | |
| 5 mM | 0.5460 mL | 2.7299 mL | 5.4597 mL | |
| 10 mM | 0.2730 mL | 1.3649 mL | 2.7299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
